Rheumnow Podcast
EULAR 2024 RA Topic Panel
Jun 24, 2024
Panel discussion led by rheumatology experts Drs. Aurelie Najm, David Liew, and Jonathan Kay at EULAR 2024 meeting. Topics include disappointing trial results for bio-naive patients, challenges in treatment selection, importance of addressing depression, impact of medications on vaccination responses, debate on therapeutic drug monitoring in RA treatment, and use of innovative apps for remote patient monitoring in rheumatoid arthritis.
45:12
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Abatacept and Adalimumab showed similar ACR50 responses in bio-naive RA patients, regardless of shared epitope or drowel seropositivity.
- Depression in RA patients significantly impacts disease outcomes, emphasizing the importance of identification and treatment for improved quality of life.
Deep dives
Amplified Study: Abatacept vs. Adalimumab Response
Patients with rheumatoid arthritis found no significant difference in response between carriers of shared epitope and drowel seropositivity in the Amplified study, where Abatacept was compared to Adalimumab in bio-naive patients. Despite hopes for Abatacept to outperform, ACR50 responses were similar at 60% for both groups, but a subset with very high ACPAs showed promising trends for better response.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
